Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
30.9M
-
Shares change
-
-78.5K
-
Total reported value, excl. options
-
$415M
-
Value change
-
+$169K
-
Put/Call ratio
-
1.12
-
Number of buys
-
52
-
Number of sells
-
-34
-
Price
-
$13.42
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q1 2018
107 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q1 2018.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.9M shares
of 126M outstanding shares and own 24.43% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.81M shares), Palo Alto Investors LP (3.68M shares), FMR LLC (3.03M shares), BlackRock Inc. (2.76M shares), FRANKLIN RESOURCES INC (2.05M shares), Point72 Asset Management, L.P. (1.96M shares), VANGUARD GROUP INC (1.94M shares), MILLENNIUM MANAGEMENT LLC (1.27M shares), STATE STREET CORP (989K shares), and venBio Select Advisor LLC (561K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.